Jiangsu GDK Biotechnology Co Ltd - Asset Resilience Ratio

Latest as of June 2025: 9.82%

Jiangsu GDK Biotechnology Co Ltd (688670) has an Asset Resilience Ratio of 9.82% as of June 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read how much debt does Jiangsu GDK Biotechnology Co Ltd carry for a breakdown of total debt and financial obligations.

Liquid Assets

CN¥144.90 Million
≈ $21.20 Million USD Cash + Short-term Investments

Total Assets

CN¥1.48 Billion
≈ $216.00 Million USD All company assets

Resilience Assessment

Low
Financial Resilience Level

Asset Resilience Ratio Trend (2019–2024)

This chart shows how Jiangsu GDK Biotechnology Co Ltd's Asset Resilience Ratio has changed over time. See 688670 net assets for net asset value and shareholders' equity analysis.

Liquid Assets Composition Over Time

This chart breaks down Jiangsu GDK Biotechnology Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see 688670 stock market capitalisation.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents CN¥0.00 0%
Short-term Investments CN¥144.90 Million 9.82%
Total Liquid Assets CN¥144.90 Million 9.82%

Asset Resilience Insights

  • Limited Liquidity: Jiangsu GDK Biotechnology Co Ltd maintains only 9.82% of assets in liquid form.
  • This low level may indicate efficient asset utilization but could pose risks during economic downturns.
  • The company has significant short-term investments, indicating active treasury management.

Jiangsu GDK Biotechnology Co Ltd Industry Peers by Asset Resilience Ratio

Compare Jiangsu GDK Biotechnology Co Ltd's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Royalty Pharma Plc
NASDAQ:RPRX
Biotechnology 0.10%
Tubize-Fin
BR:TUB
Biotechnology 0.05%
Shanghai Allist Pharmaceuticals Co. Ltd. A
SHG:688578
Biotechnology 30.29%
Hebei Changshan Biochem Pharma
SHE:300255
Biotechnology -0.03%
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252
Biotechnology 4.52%
Shanghai Junshi Biosciences Co Ltd
SHG:688180
Biotechnology 4.28%
Spyre Therapeutics Inc.
NASDAQ:SYRE
Biotechnology 83.49%
Soleno Therapeutics Inc
NASDAQ:SLNO
Biotechnology 41.74%

Annual Asset Resilience Ratio for Jiangsu GDK Biotechnology Co Ltd (2019–2024)

The table below shows the annual Asset Resilience Ratio data for Jiangsu GDK Biotechnology Co Ltd.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2024-12-31 12.75% CN¥195.39 Million
≈ $28.59 Million
CN¥1.53 Billion
≈ $224.31 Million
+2.00pp
2023-12-31 10.75% CN¥175.42 Million
≈ $25.67 Million
CN¥1.63 Billion
≈ $238.75 Million
-10.63pp
2022-12-31 21.38% CN¥390.57 Million
≈ $57.15 Million
CN¥1.83 Billion
≈ $267.31 Million
-16.08pp
2021-12-31 37.46% CN¥657.31 Million
≈ $96.19 Million
CN¥1.75 Billion
≈ $256.74 Million
+32.32pp
2020-12-31 5.14% CN¥40.00 Million
≈ $5.85 Million
CN¥777.98 Million
≈ $113.84 Million
+2.84pp
2019-12-31 2.30% CN¥9.13 Million
≈ $1.34 Million
CN¥397.30 Million
≈ $58.14 Million
--
pp = percentage points

About Jiangsu GDK Biotechnology Co Ltd

SHG:688670 China Biotechnology
Market Cap
$330.99 Million
CN¥2.26 Billion CNY
Market Cap Rank
#14590 Global
#4550 in China
Share Price
CN¥18.36
Change (1 day)
+2.46%
52-Week Range
CN¥12.24 - CN¥30.90
All Time High
CN¥75.07
About

Jiangsu Gdk Biological Technology Co., Ltd engages in the research, development, production, and sale of human vaccines. The company offers quadrivalent influenza virus split vaccines. Its human vaccine products are used for the prevention of various infectious diseases, including influenza, rabies, chickenpox, herpes zoster, and pneumonia. The company was founded in 2008 and is based in Taizhou,… Read more